Susquehanna International Group
IPHA

Susquehanna International Group’s Innate Pharma IPHA Stock Holding History

Susquehanna International Group’s Portfolio IPHA Stock Details IPHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-13,315
Closed -$37.8K – 12593
2023
Q1 		$37.8K Hold
13,315
– – ﹤0.01% 11819
2022
Q4 		$49.7K Buy
+13,315
New +$30.3K ﹤0.01% 11402

Other funds holding IPHA

Optiver Holding
Optiver Holding Amsterdam, Netherlands $289B AUM 33.63% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ETC
Exchange Traded Concepts Oklahoma City, Oklahoma $21.9B AUM 68.6% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
SPIA
Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Susquehanna International Group's IPHA Position: Q2 2023 in Review

Susquehanna International Group sold out of Innate Pharma (IPHA) in Q2 2023, closing a stake of 13,315 shares — an estimated $37.8K sold.

Susquehanna International Group first reported a position in IPHA in Q4 2022 and held it in 2 quarters. The position peaked at $49.7K in Q4 2022. 9 funds tracked by Wall St. Rank hold IPHA as of Q2 2023.

  • Susquehanna International Group reported no remaining Innate Pharma position as of Q2 2023 after selling out during the quarter.
  • Susquehanna International Group sold 13,315 Innate Pharma shares in Q2 2023, an estimated $37.8K.
  • Susquehanna International Group first reported a position in Innate Pharma in Q4 2022 and held it in 2 quarters.
  • Susquehanna International Group's Innate Pharma position peaked at $49.7K in Q4 2022.
  • 9 funds tracked by Wall St. Rank held Innate Pharma as of Q2 2023.

Based on Susquehanna International Group's 13F filing for Q2 2023, filed 11 Aug 2023.